Biogen has informed the European Medicines Agency (EMA) that it is withdrawing its application for marketing authorisation for aducanumab for the treatement of Alzheimer’s disease The EMA had previously found on 16 December 2021 that the benefits of aducanumab did not outweigh its risks and recommended refusing marketing authorisation. Biogen then requested a re-examination. Following…
Category: Alzheimer’s
Dementia Research: New Alzheimer Europe discussion paper
New discussion paper from Alzheimer Europe
Grifols presents latest Alzheimer’s clinical trial data
Neuroimaging shows AMBAR clinical trial’s positive effects in patients with mild-to-moderate Alzheimer’s disease
